PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC.
Lau SCM, Rabindranath M, Weiss J, Li JJN, Fung AS, Mullen D, Alshamlan N, Ruff HM, Tong LCB, Pal P, Cabanero MR, Hsu YR, Sacher AG, Shepherd FA, Liu G, Bradbury PA, Yasufuku K, Czarnecka-Kujawa K, Mi Ko H, Tsao MS, Leighl NB, Schwock J.
Lau SCM, et al. Among authors: tong lcb.
Lung Cancer. 2022 Sep;171:42-46. doi: 10.1016/j.lungcan.2022.07.018. Epub 2022 Jul 25.
Lung Cancer. 2022.
PMID: 35907387
Review.